Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma

Update Il y a 4 ans
Reference: NCT00280878

Woman and Man

  • | Country :
  • Australia
  • | organs :
  • -
  • | Specialty :
  • -

Extract

This is a Phase II pilot study evaluating the safety of a risk-adjusted outpatient-based approach to lymphoma salvage therapy with VGF (vinorelbine, gemcitabine and pegfilgrastim) and/or F-GIV (gemcitabine, Ifosfamide, vinorelbine and pegfilgrastim) in combination with Rituximab (R-VGF/R-F-GIV).


Inclusion criteria

  • Non-Hodgkin's Lymphoma (CD20+)

Links